NeOnc Technologies Holdings, Inc. (NTHI)

NGM – Цена в реальном времени. Валюта: USD

5.61

+0.10 (1.81%)

Рынок открыт: May 13, 2026, 9:58 AM EDT

07.05.2026

Biotech's Next Wave May Already be in Motion

DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape.

06.05.2026

Where Executives Are Doubling Down on Their Companies' Fortunes

DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money to work. Executives and strategic stakeholders have been accumulating shares in meaningful size, ranging from six-figure buys to billion-dollar commitments.

05.05.2026

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring strong alignment with shareholders ahead of upcoming clinical and regulatory milestones.

01.04.2026

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced financial results for the quarter and year ended December 31, 2025, and provided an update on recent operational achievements and upcoming milestones.

13.03.2026

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations.

12.03.2026

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Dallas, Texas--(Newsfile Corp. - March 12, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain.

04.03.2026

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

NeOnc Technologies Holdings, Inc. (NTHI)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NeOnc Technologies Holdings, Inc. (NTHI)

Biotech's Next Wave May Already be in Motion

Where Executives Are Doubling Down on Their Companies' Fortunes

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Видео

No Data

Пресс-релизы

Biotech's Next Wave May Already be in Motion

Biotech's Next Wave May Already be in Motion

Where Executives Are Doubling Down on Their Companies' Fortunes

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Видео

No Data

Пресс-релизы

Biotech's Next Wave May Already be in Motion

Where Executives Are Doubling Down on Their Companies' Fortunes

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

Search stocks

NeOnc Technologies Holdings, Inc. (NTHI)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NeOnc Technologies Holdings, Inc. (NTHI)

Biotech's Next Wave May Already be in Motion

Where Executives Are Doubling Down on Their Companies' Fortunes

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Видео

No Data

Пресс-релизы

Biotech's Next Wave May Already be in Motion

Biotech's Next Wave May Already be in Motion

Where Executives Are Doubling Down on Their Companies' Fortunes

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Видео

No Data

Пресс-релизы

Biotech's Next Wave May Already be in Motion

Where Executives Are Doubling Down on Their Companies' Fortunes

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc Provides Business Update and Reports Q4 2025 Financial Results